Stanford Researchers Create Versatile CRISPR Delivery System with Commercial Antibodies

A Stanford-led team has developed designer antibody-routed nanoparticles (DARTs), a novel CRISPR-Cas delivery system that can target specific cells using readily available commercial antibodies. This innovative method allows for rapid cell-type-specific delivery for therapeutic genome editing by simply incubating particles with an antibody. The DART system successfully identified CD56 as an entry point for editing neural progenitor cells in fetal mouse brains, marking a significant advancement in gene-editing technology.